Comparison of MMR and Cidofovir as Adjuncts for Recurrent Respiratory Papillomatosis

Abstract

Objectives:

1) Describe experience at a single institution using measles, mumps, rubella (MMR) vaccine and cidofovir as adjunct treatments after CO2 laser ablation for recurrent respiratory papillomatosis (RRP) in children. 2) Compare outcome measures and remission rates between MMR and cidofovir.

Methods:

Retrospective review from 2004-2012 at a tertiary referral children’s hospital. Subjects were younger than 18 years and required at least 1 year of follow-up to be included for review. Remission rate was determined by a Derkay score of 0 for at least 6 months.

Results:

Of 20 subjects identified with RRP, 15 had been followed for at least 1 year. Five subjects were treated with cidofovir, 6 patients with MMR, and 3 with a combination of the above. One did not receive adjunct injections. Initial Derkay score was 12.6 for the cidofovir group and 11.0 for the MMR group (P = .61). Average number of debridements received was 11.8 for the cidofovir group and 17.6 for the MMR group (P = .33). Average days between treatments was 63.0 for cidofovir and 81.3 for MMR (P = .43). Total months observed was 44.0 for cidofovir and 64.6 for MMR (P = .29). Remission rate was 20% with the cidofovir group and 50% for the MMR group (P = .54).

Conclusions:

There is no statistically significant difference in number of debridements needed, average number of days between debridements, or remission rates between MMR and cidofovir as adjunctive treatments for recurrent respiratory papillomatosis in children.